NASDAQ:PPH VanEck Pharmaceutical ETF (PPH) Price, Holdings, & News → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free PPH Stock Alerts $86.92 +1.00 (+1.16%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$86.21▼$86.9650-Day Range$84.87▼$90.8952-Week Range$74.05▼$91.16Volume190,081 shsAverage Volume124,241 shsMarket Capitalization$511.96 millionAssets Under Management$492.85 millionDividend Yield1.79%Net Expense Ratio0.35% Stock AnalysisStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial MediaStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial Media Get VanEck Pharmaceutical ETF alerts: Email Address About VanEck Pharmaceutical ETF (NASDAQ:PPH)The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.Read More PPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PPH ETF News HeadlinesApril 23, 2024 | seekingalpha.comPPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total ReturnsApril 18, 2024 | theglobeandmail.comCanada’s updated guidance on ESG-related investment fund disclosureApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 3, 2024 | msn.comVanEck Pharmaceutical ETF declares quarterly distribution of $0.5328April 1, 2024 | msn.comVanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.5328March 7, 2024 | investorplace.comThe Top 3 ETFs to Buy in March 2024February 28, 2024 | markets.businessinsider.com11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher YieldsFebruary 28, 2024 | stocknews.comNavigate to Success With These 4 Pharma Stocks to BuyApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.February 26, 2024 | investorplace.comThe 3 Hottest Healthcare ETFs to Buy in 2024See More Headlines Receive PPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerVan Eck Fund NameVanEck Pharmaceutical ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:PPH Inception Date12/20/2011 Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkMarket Vectors US Listed Pharmaceutical 25 Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionGlobal Number of Holdings26 Fund Statistics Assets Under Management$492.85 million Average Daily Volume$106,985.50 Discount/Premium0.03% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianState Street Bank and Trust Company DistributorVan Eck Securities Corporation Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerIMC Options OptionableOptionable Options Volume3 Put Options14 Call Options3 Short Interest1,580,000 shs Miscellaneous Outstanding Shares5,890,000Beta0.72 Creation Unit50,000 Creation Fee$500.00 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry VanEck Pharmaceutical ETF ExpensesTypePPHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.35%0.56%0.54%0.48%0.51%Other Expenses0.00%0.40%0.54%0.34%0.58%Total Expense0.35%0.72%0.70%0.58%0.70%Fee Waiver0.00%-0.53%-0.55%-0.22%-0.57%Net Expense0.35%0.60%0.60%0.54%0.58% VanEck Pharmaceutical ETF (PPH) Holdings & ExposureTop 10 PPH HoldingsEli Lilly and Company(NYSE:LLY)Holding Weight: 12.05%Novo Nordisk A/S(NYSE:NVO)Holding Weight: 9.70%Johnson & Johnson(NYSE:JNJ)Holding Weight: 6.48%Merck & Co., Inc.(NYSE:MRK)Holding Weight: 6.28%AbbVie(NYSE:ABBV)Holding Weight: 5.81%AstraZeneca(NASDAQ:AZN)Holding Weight: 5.51%Cencora(NYSE:COR)Holding Weight: 4.81%Novartis AG ADRHolding Weight: 4.81%McKesson(NYSE:MCK)Holding Weight: 4.74%Haleon(NYSE:HLN)Holding Weight: 4.60%PPH Sector ExposurePPH Industry ExposureFull Holdings Details Similar ETFsVanEck Biotech ETFNASDAQ:BBHInvesco S&P SmallCap Health Care ETFNASDAQ:PSCHInvesco Dorsey Wright Healthcare Momentum ETFNASDAQ:PTHProShares Ultra Nasdaq BiotechnologyNASDAQ:BIBPrincipal Healthcare Innovators ETFNASDAQ:BTECInstitutional OwnershipRaymond James Financial Services Advisors Inc.Sold 362 shares on 4/23/2024Ownership: 0.302%Global Retirement Partners LLCBought 375 shares on 4/23/2024Ownership: 0.007%Edge Financial Advisors LLCBought 2,739 shares on 4/22/2024Ownership: 0.047%Aspiriant LLCBought 320 shares on 4/15/2024Ownership: 0.099%Summit Financial Group Inc.Bought 3,835 shares on 4/5/2024Ownership: 0.074%View All Institutional Transactions PPH ETF - Frequently Asked Questions How have PPH shares performed in 2024? VanEck Pharmaceutical ETF's stock was trading at $81.37 at the beginning of the year. Since then, PPH shares have increased by 6.8% and is now trading at $86.92. View the best growth stocks for 2024 here. Are investors shorting VanEck Pharmaceutical ETF? VanEck Pharmaceutical ETF saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 8,700 shares, a drop of 99.4% from the March 15th total of 1,570,000 shares. Based on an average trading volume of 128,200 shares, the days-to-cover ratio is presently 0.1 days. View VanEck Pharmaceutical ETF's Short Interest. How often does VanEck Pharmaceutical ETF pay dividends? What is the dividend yield for VanEck Pharmaceutical ETF? VanEck Pharmaceutical ETF announced a dividend on Thursday, March 28th. Shareholders of record on Tuesday, April 2nd will be given a dividend of $0.5328 per share on Friday, April 5th. The ex-dividend date is Monday, April 1st. Read our dividend analysis for PPH. What does PPH invest in? VanEck Pharmaceutical ETF is a equity fund issued by Van Eck. PPH focuses on health care investments and follows the Market Vectors US Listed Pharmaceutical 25 Index. The fund's investments total to approximately $492.85 million assets under management. What stocks does VanEck Pharmaceutical ETF hold? PPH invests in 26 holdings. Some of the stocks in their portfolio include Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), AstraZeneca (AZN), Cencora (COR), McKesson (MCK), Haleon (HLN) and Sanofi (SNY). What is the management fee for VanEck Pharmaceutical ETF? VanEck Pharmaceutical ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for PPH is 0.35%. What is Bruce Gordon's approval rating as VanEck Pharmaceutical ETF's CEO? 38 employees have rated VanEck Pharmaceutical ETF Chief Executive Officer Bruce Gordon on Glassdoor.com. Bruce Gordon has an approval rating of 98% among the company's employees. This puts Bruce Gordon in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of VanEck Pharmaceutical ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Pharmaceutical ETF investors own include Bank of America (BAC), Alibaba Group (BABA), AeroVironment (AVAV), Activision Blizzard (ATVI), ARK Innovation ETF (ARKK), Applied Materials (AMAT), Applied Graphene Materials (AGM), Air Canada (AC) and Abbott Laboratories (ABT). Who are VanEck Pharmaceutical ETF's major shareholders? VanEck Pharmaceutical ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (0.30%), Aspiriant LLC (0.10%), Summit Financial Group Inc. (0.07%), Edge Financial Advisors LLC (0.05%) and Global Retirement Partners LLC (0.01%). How do I buy shares of VanEck Pharmaceutical ETF? Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PPH) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Pharmaceutical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
